ImmuPharma plc

ImmuPharma plc is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutic solutions. The firm's innovative treatments address a range of medical fields, including autoimmune and inflammatory disorders, as well as anti-infective applications. Leading its pipeline is Lupuzor, an autophagy immunomodulator, which is presently undergoing Phase III clinical trials for the management of lupus, a chronic autoimmune inflammatory disease. Beyond its lead candidate, ImmuPharma is advancing BioAMB, a peptide-based drug designed for Amphotericin-B formulations used against fungal infections caused by the aspergillus family. Another product in development is BioCin, a peptide-based antibacterial agent intended for situations of high medical need and as a last-line defense. The company maintains a collaborative relationship with the Centre National de la Recherche Scientifique to develop a peptide technology platform targeting diabetes through glucagon-like peptide -1 agonists and glucagon antagonists for both type I and type II diabetes. ImmuPharma also holds a license and development agreement with Avion Pharmaceuticals LLC. Founded in 1999, ImmuPharma plc is headquartered in London, United Kingdom.